bioRxiv / medRxiv
open access
Interpretable biomarker programs predict treatment response in lupus nephritis: patient-level validation across four regimens
A large share of late-stage clinical trial failures reflects not the underlying biology of the target but the composition of the enrolled population: trials recruit patients in whom the drug cannot work. Methods that identify likely responders before treatment therefore address a failure mode that b
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- SII and SIRI as Prognostic Biomarkers in Lupus Nephritis#832661
- Beyond the trial: a single-center retrospective review of real-world lupus nephritis management and outcomes.#430819
- Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.#993252
- Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone#1060776
- Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis#1230990
Record · ID 1336106
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive